Procalcitonin, and cytokines document a dynamic inflammatory state in non-infected cirrhotic patients with ascites

World Journal of Gastroenterology

Volumn 20, Issue 9, 2014, Pages 2374-2382

  Attar, Bashar M ^a,b   Moore, Christopher M ^b   George, Magdalena ^b   Ion Nedelcu, Nicolae ^c   Turbay, Rafael ^a   Zachariah, Annamma ^a   Ramadori, Guiliano ^d   Fareed, Jawed ^e   Van Thiel, David H ^b  

^a Jr Hospital of Cook County   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY   (Romania)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

^e LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Ascites; Bacterial translocation; Cirrhosis; Inflammatory markers; Procalcitonin

Indexed keywords

ALANINE AMINOTRANSFERASE; CYTOKINE; EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN; PROCALCITONIN; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; BIOLOGICAL MARKER; CALCITONIN; PROTEIN PRECURSOR;

ADULT; AGED; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILD TURCOTTE PUGH SCORE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; INTERNATIONAL NORMALIZED RATIO; LEUKOCYTE COUNT; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MODEL FOR END STAGE LIVER DISEASE SCORE; NONALCOHOLIC FATTY LIVER; PROTHROMBIN TIME; UREA NITROGEN BLOOD LEVEL; ASCITES FLUID; BLOOD; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; GERMANY; HOSPITAL; IMMUNOLOGY; PREDICTIVE VALUE; PROGNOSIS; RISK FACTOR;

ADULT; AGED; ASCITES; ASCITIC FLUID; BIOLOGICAL MARKERS; CALCITONIN; CYTOKINES; DIAGNOSIS, DIFFERENTIAL; FEMALE; GERMANY; HOSPITALS, URBAN; HUMANS; INFLAMMATION MEDIATORS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN PRECURSORS; RISK FACTORS;

EID: 84895864425     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i9.2374     Document Type: Article

References (45)

1. Pinzani M, Vizzutti F. Fibrosis and cirrhosis reversibility: clinical features and implications. Clin Liver Dis 2008; 12: 901-913, x [PMID: 18984473 DOI: 10.1016/j.cld.2008.07.006]
2. Pinzani M, Rombouts K, Colagrande S. Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol 2005; 42 Suppl: S22-S36 [PMID: 15777570]
3. Lefton HB, Rosa A, Cohen M. Diagnosis and epidemiology of cirrhosis. Med Clin North Am 2009; 93: 787-799, vii [PMID: 19577114 DOI: 10.1016/j.mcna.2009.03.002]
4. Dancygier H. Clinical Hepatology: Principles and Practice of Hepatobiliary Diseases. New York: Springer Science, 2010: 514
5. Runyon BA, Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49: 2087-2107 [PMID: 19475696 DOI: 10.1002/hep.22853]
6. Guarner C, Soriano G. Bacterial translocation and its consequences in patients with cirrhosis. Eur J Gastroenterol Hepatol 2005; 17: 27-31 [PMID: 15647636]
7. Cirera I, Bauer TM, Navasa M, Vila J, Grande L, Taurá P, Fuster J, García-Valdecasas JC, Lacy A, Suárez MJ, Rimola A, Rodés J. Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol 2001; 34: 32-37 [PMID: 11211904]
8. Runyon BA, Squier S, Borzio M. Translocation of gut bacteria in rats with cirrhosis to mesenteric lymph nodes partially explains the pathogenesis of spontaneous bacterial peritonitis. J Hepatol 1994; 21: 792-796 [PMID: 7890896]
9. Constantinou A, Mehta R, Runyan C, Rao K, Vaughan A, Moon R. Flavonoids as DNA topoisomerase antagonists and poisons: structure-activity relationships. J Nat Prod 1995; 58: 217-225 [PMID: 7769390]
10. Woodcock NP, Robertson J, Morgan DR, Gregg KL, Mitchell CJ, MacFie J. Bacterial translocation and immunohistochemical measurement of gut immune function. J Clin Pathol 2001; 54: 619-623 [PMID: 11477118]
11. Garcia-Tsao G, Albillos A, Barden GE, West AB. Bacterial translocation in acute and chronic portal hypertension. Hepatology 1993; 17: 1081-1085 [PMID: 8514258]
12. Ramachandran A, Balasubramanian KA. Intestinal dysfunction in liver cirrhosis: Its role in spontaneous bacterial peritonitis. J Gastroenterol Hepatol 2001; 16: 607-612 [PMID: 11422611]
13. Pardo A, Bartolí R, Lorenzo-Zúñiga V, Planas R, Viñado B, Riba J, Cabré E, Santos J, Luque T, Ausina V, Gassull MA. Effect of cisapride on intestinal bacterial overgrowth and bacterial translocation in cirrhosis. Hepatology 2000; 31: 858-863 [PMID: 10733540]
14. Chelarescu O, Chelarescu D, Tircoveanu E, Stratan I. Propranolol administration on post surgical infections in cirrhotic patients. J Hepatol 2003; 38 Suppl 2: A173 [DOI: 10.1016/ S0168-8278(03)80589-5]
15. Guarner C, Runyon BA, Heck M, Young S, Sheikh MY. Effect of long-term trimethoprim-sulfamethoxazole prophylaxis on ascites formation, bacterial translocation, spontaneous bacterial peritonitis, and survival in cirrhotic rats. Dig Dis Sci 1999; 44: 1957-1962 [PMID: 10548343]
16. Llamas MA, Aller MA, Marquina D, Nava MP, Arias J. Bacterial translocation to mesenteric lymph nodes increases in chronic portal hypertensive rats. Dig Dis Sci 2010; 55: 2244-2254 [PMID: 19834810 DOI: 10.1007/s10620-009-1001-3]
17. Palma MD, Aller MA, Vara E, Nava MP, Garcia C, Arias-Diaz J, Balibrea JL, Arias J. Portal hypertension produces an evolutive hepato-intestinal pro-and anti-inflammatory response in the rat. Cytokine 2005; 31: 213-226 [PMID: 15950486]
18. Francés R, González-Navajas JM, Zapater P, Muñoz C, Caño R, Pascual S, Márquez D, Santana F, Pérez-Mateo M, Such J. Bacterial DNA induces the complement system activation in serum and ascitic fluid from patients with advanced cirrhosis. J Clin Immunol 2007; 27: 438-444 [PMID: 17404822]
19. Papp M, Vitalis Z, Altorjay I, Tornai I, Udvardy M, Harsfalvi J, Vida A, Kappelmayer J, Lakatos PL, Antal-Szalmas P. Acute phase proteins in the diagnosis and prediction of cirrhosis associated bacterial infections. Liver Int 2012; 32: 603-611 [PMID: 22145664 DOI: 10.1111/j.1478-3231.2011.02689.x.]
20. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004; 39: 206-217 [PMID: 15307030]
21. Elefsiniotis IS, Skounakis M, Vezali E, Pantazis KD, Petrocheilou A, Pirounaki M, Papatsibas G, Kontou-Kastellanou C, Moulakakis A. Clinical significance of serum procalcitonin levels in patients with acute or chronic liver disease. Eur J Gastroenterol Hepatol 2006; 18: 525-530 [PMID: 16607149]
22. Connert S, Stremmel W, Elsing C. Procalcitonin is a valid marker of infection in decompensated cirrhosis. Z Gastroenterol 2003; 41: 165-170 [PMID: 12592597]
23. Viallon A, Zeni F, Pouzet V, Lambert C, Quenet S, Aubert G, Guyomarch S, Tardy B, Bertrand JC. Serum and ascitic procalcitonin levels in cirrhotic patients with spontaneous bacterial peritonitis: diagnostic value and relationship to pro-inflammatory cytokines. Intensive Care Med 2000; 26: 1082-1088 [PMID: 11030164]
24. Gendrel D, Raymond J, Coste J, Moulin F, Lorrot M, Guérin S, Ravilly S, Lefèvre H, Royer C, Lacombe C, Palmer P, Bohuon C. Comparison of procalcitonin with C-reactive protein, interleukin 6 and interferon-alpha for differentiation of bacterial vs. viral infections. Pediatr Infect Dis J 1999; 18: 875-881 [PMID: 10530583]
25. Wu JY, Lee SH, Shen CJ, Hsieh YC, Yo PH, Cheng HY, Chan RC, Lee CC, Chang SS. Use of serum procalcitonin to detect bacterial infection in patients with autoimmune diseases: a systematic review and meta-analysis. Arthritis Rheum 2012; 64: 3034-3042 [PMID: 22605405 DOI: 10.1002/art.34512.]
26. Reinhart K, Meisner M. Biomarkers in the critically ill patient: procalcitonin. Crit Care Clin 2011; 27: 253-263 [PMID: 21440200 DOI: 10.1016/j.ccc.2011.01.002.]
27. Japiassu AM, Bozza FA. The many facets of procalcitonin in the critically ill population. Crit Care Med 2012; 40: 2903-2905 [PMID: 22986656 DOI: 10.1097/CCM.0b013e3182631e56.]
28. Su DH, Zhuo C, Liao K, Cheng WB, Cheng H, Zhao XF. Value of serum procalcitonin levels in predicting spontaneous bacterial peritonitis. Hepatogastroenterology 2013; 60: 641-646 [PMID: 23159389 DOI: 10.5754/hge12645]
29. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci USA 1996; 93: 2879-2883 [PMID: 8610135]
30. Neugebauer H, Hartmann P, Krenn S, Glück T, Schölmerich J, Straub R, Wiest R. Bacterial translocation increases phagocytic activity of polymorphonuclear leucocytes in portal hypertension: priming independent of liver cirrhosis. Liver Int 2008; 28: 1149-1157 [PMID: 18662280 DOI: 10.1111/ j.1478-3231.2008.01829.x]
31. Sparwasser T, Miethke T, Lipford G, Erdmann A, Häcker H, Heeg K, Wagner H. Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock. Eur J Immunol 1997; 27: 1671-1679 [PMID: 9247576]
32. Francés R, Muñoz C, Zapater P, Uceda F, Gascón I, Pascual S, Pérez-Mateo M, Such J. Bacterial DNA activates cell mediated immune response and nitric oxide overproduction in peritoneal macrophages from patients with cirrhosis and ascites. Gut 2004; 53: 860-864 [PMID: 15138214]
33. Cowdery JS, Chace JH, Yi AK, Krieg AM. Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. J Immunol 1996; 156: 4570-4575 [PMID: 8648098]
34. Stacey KJ, Sweet MJ, Hume DA. Macrophages ingest and are activated by bacterial DNA. J Immunol 1996; 157: 2116-2122 [PMID: 8757335]
35. Wagner H. Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity. Curr Opin Microbiol 2002; 5: 62-69 [PMID: 11834371]
36. Gordon FD. Ascites. Clin Liver Dis 2012; 16: 285-299 [PMID: 22541699]
37. Parsi MA, Saadeh SN, Zein NN, Davis GL, Lopez R, Boone J, Lepe MR, Guo L, Ashfaq M, Klintmalm G, McCullough AJ. Ascitic fluid lactoferrin for diagnosis of spontaneous bacterial peritonitis. Gastroenterology 2008; 135: 803-807 [PMID: 18590731 DOI: 10.1053/j.gastro.2008.05.045]
38. Kallwitz ER. Ascites fluid lactoferrin: data emerges for a logical biomarker. Gastroenterology 2008; 135: 731-733 [PMID: 18692054 DOI: 10.1053/j.gastro.2008.07.037]
39. Runyon BA, Antillon MR, McHutchison JG. Diuresis increases ascitic fluid opsonic activity in patients who survive spontaneous bacterial peritonitis. J Hepatol 1992; 14: 249-252 [PMID: 1500689]
40. Ljubicić N, Bilić A, Kopjar B. Diuretics vs. paracentesis followed by diuretics in cirrhosis: effect on ascites opsonic activity and immunoglobulin and complement concentrations. Hepatology 1994; 19: 346-353 [PMID: 8294092]
41. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31: 864-871 [PMID: 10733541]
42. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, Dickson ER, Kim WR. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-470 [PMID: 11172350]
43. Said A, Williams J, Holden J, Remington P, Gangnon R, Musat A, Lucey MR. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol 2004; 40: 897-903 [PMID: 15158328]
44. Pomfret EA, Washburn K, Wald C, Nalesnik MA, Douglas D, Russo M, Roberts J, Reich DJ, Schwartz ME, Mieles L, Lee FT, Florman S, Yao F, Harper A, Edwards E, Freeman R, Lake J. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010; 16: 262-278 [PMID: 20209641 DOI: 10.1002/lt.21999]
45. Sersté T, Gustot T, Rautou PE, Francoz C, Njimi H, Durand F, Valla D, Lebrec D, Moreau R. Severe hyponatremia is a better predictor of mortality than MELDNa in patients with cirrhosis and refractory ascites. J Hepatol 2012; 57: 274-280 [PMID: 22521353 DOI: 10.1016/j.jhep.2012.03.018]